Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it will present at the PCG Spotlight Series Conference taking place on Thursday, November 21^st at the Harvard Club, 35 West 44th Street, New York, NY at 12:25pm ET. Mr. Jed A. Latkin, Chief Executive Officer, will be presenting and meeting with investors throughout the conference.

“We look forward to presenting our clinical programs at the PCG Spotlight Series Conference,” commented Jed A. Latkin, Chief Executive Officer of Navidea. “We recently announced positive data from the first interim analysis of the NAV3-31 Phase 2B diagnostic study for patients with rheumatoid arthritis, and will provide an overview of planned milestones in the program. Navidea also continues to further partnership discussions and will review the recent research collaboration with IMV, Inc. using their platform-based immunotherapies.”

Jeff Ramson, Founder and CEO of PCG Advisory, commented: “Each of the eight companies presenting at our Spotlight Series Conference has an innovative approach to its mission. With 20 minute presentations and networking among the participants and a group of high quality investors, this is a great opportunity for attendees to get to know the mission of these unique companies.”

Interested investors may RSVP to [e-mail] to attend.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.